Literature DB >> 22933235

Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.

Vlachaki Efthimia, Nikolaos Neokleous, Alexandra Agapidou, Marina Economou, Evaggelia Vetsiou, Aikaterini Teli, Vasileios Perifanis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22933235     DOI： 10.1007/s00277-012-1558-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

Review 1.  Impact of bone disease and pain in thalassemia.

Authors:  Antonio Piga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Deferasirox nephrotoxicity-the knowns and unknowns.

Authors:  Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz
Journal:  Nat Rev Nephrol       Date:  2014-07-22       Impact factor: 28.314

3.  Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR).

Authors:  Amit Lahoti; Yael T Harris; Phyllis W Speiser; Evangelia Atsidaftos; Jeffrey M Lipton; Adrianna Vlachos
Journal:  Pediatr Blood Cancer       Date:  2015-10-23       Impact factor: 3.167

4.  Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.

Authors:  Osama Tanous; Yossi Azulay; Raphael Halevy; Tal Dujovny; Neta Swartz; Raul Colodner; Ariel Koren; Carina Levin
Journal:  BMC Nephrol       Date:  2021-12-20       Impact factor: 2.388

5.  Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria.

Authors:  Ludovica Aliberti; Irene Gagliardi; Maria Rita Gamberini; Andrea Ziggiotto; Martina Verrienti; Aldo Carnevale; Marta Bondanelli; Maria Chiara Zatelli; Maria Rosaria Ambrosio
Journal:  Br J Haematol       Date:  2022-06-29       Impact factor: 8.615
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.